应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
未开盘 10-15 16:08:33
0.385
-0.010
-2.53%
最高
0.395
最低
0.350
成交量
32.10万
今开
0.385
昨收
0.395
日振幅
11.39%
总市值
2.38亿
流通市值
2.38亿
总股本
6.18亿
成交额
11.65万
换手率
0.05%
流通股本
6.18亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
星展：国产创新药出海浪潮持续 短期或面临调整压力 中长期前景正面
智通财经 · 10-15 21:22
星展：国产创新药出海浪潮持续 短期或面临调整压力 中长期前景正面
千红制药：该创新药I类沟通交流会议为公司QHRD211项目
证券之星 · 10-15 20:48
千红制药：该创新药I类沟通交流会议为公司QHRD211项目
热景生物最新公告：子公司创新药SGC001新增适应症Ⅱ期临床完成首例受试者入组给药
证券之星 · 10-15 20:30
热景生物最新公告：子公司创新药SGC001新增适应症Ⅱ期临床完成首例受试者入组给药
跌到位了？创新药逆市活跃，药ETF（562050）成功收红，港股通创新药ETF华宝跑赢大市！ESMO大会下周启幕
新浪基金 · 10-15 19:33
跌到位了？创新药逆市活跃，药ETF（562050）成功收红，港股通创新药ETF华宝跑赢大市！ESMO大会下周启幕
ESMO及三季报双窗口来临，创新药板块迎密集催化丨盘中雷达
东方财富网 · 10-15 11:29
ESMO及三季报双窗口来临，创新药板块迎密集催化丨盘中雷达
ETF热点解读|创新药板块上涨，创新药ETF、港股医药ETF、港股通创新药ETF、恒生生物科技ETF上涨
格隆汇 · 10-15 10:00
ETF热点解读|创新药板块上涨，创新药ETF、港股医药ETF、港股通创新药ETF、恒生生物科技ETF上涨
创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善
金吾财讯 · 10-15 09:59
创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善
天风·医药 | 创新药/制药行业及个股2026半年度回顾与展望——天风医药细分领域分析与展望
天风研究 · 10-15 08:00
天风·医药 | 创新药/制药行业及个股2026半年度回顾与展望——天风医药细分领域分析与展望
股市必读：亚太药业新发布《关于签署创新药技术交易合作意向书的公告》
证券之星 · 10-14 02:35
股市必读：亚太药业新发布《关于签署创新药技术交易合作意向书的公告》
利润说了算！创新药板块新旧交替，谁会在未来更赚钱？
东方财富网 · 10-13 17:47
利润说了算！创新药板块新旧交替，谁会在未来更赚钱？
润都股份：公司创新药医保谈判相关信息以官方通知和公司公告为准
证券之星 · 10-13 15:48
润都股份：公司创新药医保谈判相关信息以官方通知和公司公告为准
港股创新药概念股集体走低，华昊中天医药-B跌超11%、金斯瑞生物科技跌超10%
老虎资讯综合 · 10-13 09:38
港股创新药概念股集体走低，华昊中天医药-B跌超11%、金斯瑞生物科技跌超10%
国产创新药“出海”如何走远走实？
证券日报 · 10-12
国产创新药“出海”如何走远走实？
清华证研院：创新药板块景气修复与医疗器械自主可控构成9月主线
东方财富网 · 10-10
清华证研院：创新药板块景气修复与医疗器械自主可控构成9月主线
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
金吾财讯 · 10-09
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参
每日经济新闻 · 10-09
阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参
众生药业(002317.SZ)：一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果
智通财经 · 10-08
众生药业(002317.SZ)：一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果
永泰生物-B（06978）：王敏慧增持，好仓比例升至8.22%
港股披露 · 10-08
永泰生物-B（06978）：王敏慧增持，好仓比例升至8.22%
永泰生物-B：张军政增持，好仓比例升至8.22%
港股披露 · 10-08
永泰生物-B：张军政增持，好仓比例升至8.22%
港股异动 | 创新药概念股午后跌幅扩大 歌礼制药-B(01672.HK)跌超10% 信达生物(01801.HK)跌近4%
智通财经 · 10-08
港股异动 | 创新药概念股午后跌幅扩大 歌礼制药-B(01672.HK)跌超10% 信达生物(01801.HK)跌近4%
暂无数据
公司概况
公司名称：
永泰生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。
发行价格：
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.385,"timestamp":1792051713527,"preClose":0.395,"halted":0,"volume":321005,"delay":0,"changeRate":-0.025316455696202552,"floatShares":618000000,"shares":618000000,"eps":-0.4926783640415582,"marketStatus":"未开盘","change":-0.01,"latestTime":"10-15 16:08:33","open":0.385,"high":0.395,"low":0.35,"amount":116476,"amplitude":0.113924,"askPrice":0.385,"askSize":6000,"bidPrice":0.37,"bidSize":60000,"shortable":0,"etf":0,"ttmEps":-0.33513272670203087,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792114200000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.395,"openAndCloseTimeList":[[1792027800000,1792036800000],[1792040400000,1792051200000]],"volumeRatio":2.880518662167517,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/tweets","defaultTab":"tweets","newsList":[{"id":"2675580546","title":"星展：国产创新药出海浪潮持续 短期或面临调整压力 中长期前景正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2675580546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675580546?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:22","pubTimestamp":1792070543,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582062","title":"千红制药：该创新药I类沟通交流会议为公司QHRD211项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582062?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:48","pubTimestamp":1792068502,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)10月15日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘：您好！公司2026-09-04的I类沟通交流会议（编号2026006060）已反馈，涉及哪个创新药项目？是否属于突破性治疗相关沟通？千红制药回复：尊敬的股东，您好，该创新药I类沟通交流会议为公司QHRD211项目，具体临床进展敬情关注公司后续信披披露相关公告，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500037424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582992","title":"热景生物最新公告：子公司创新药SGC001新增适应症Ⅱ期临床完成首例受试者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582992","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582992?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:30","pubTimestamp":1792067409,"startTime":"0","endTime":"0","summary":"热景生物(688068.SH)公告称，公司控股子公司舜景医药自主研发的创新药SGC001注射液“预期重症急性胰腺炎”适应症Ⅱ期临床研究完成首例受试者入组给药。该药物为急救用单克隆抗体药物，此前已获FDA及CDE临床批准，并于2025年3月获FDA快速通道认定。本次新增适应症临床进展标志着SGC001进入多适应症开发阶段。公司提示，创新药研发周期长、风险高，短期内不会对业绩造成重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500036888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0239","06978","688068","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675758139","title":"跌到位了？创新药逆市活跃，药ETF（562050）成功收红，港股通创新药ETF华宝跑赢大市！ESMO大会下周启幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2675758139","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675758139?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:33","pubTimestamp":1792063980,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。10月15日，大市深度调整，A+H创新药资产逆市活跃，带动药ETF华宝成功收红，港股通创新药ETF华宝标的指数微跌0.4%跑赢大市。截至收盘，港股通创新药ETF华宝标的指数走出7连跌，盘中点位创近3个月新低。图：港股通创新药ETF华宝近6月日K走势今日板块未能全面上涨，主要受美联储加息预期升温压制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-15/doc-iniviekf8076114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4550","BK1161","LNGR","BK1574","IBBQ","MEDX","FDN","562050","06978","BK4585","159992","520880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675899377","title":"ESMO及三季报双窗口来临，创新药板块迎密集催化丨盘中雷达","url":"https://stock-news.laohu8.com/highlight/detail?id=2675899377","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675899377?lang=zh_cn&edition=full","pubTime":"2026-10-15 11:29","pubTimestamp":1792034942,"startTime":"0","endTime":"0","summary":"ESMO及三季报双窗口来临，创新药板块迎密集催化重磅学术盛会即将来临。ESMO2026将于10月23–27日在马德里召开，主席专场中国研究占5席，国内药企多个创新资产将以LBA形式发布，核心数据将集中发布。中泰证券表示，医药迎三季报和ESMO双窗口。10月市场核心矛盾有望由流动性与主题投资转向三季报业绩验证。三季报关注CXO/科研上游景气延续与创新药“放量+BD兑现”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610153896648231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610153896648231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["IBBQ","BK1161","BK1574","MEDX","LNGR","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675718733","title":"ETF热点解读|创新药板块上涨，创新药ETF、港股医药ETF、港股通创新药ETF、恒生生物科技ETF上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675718733","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675718733?lang=zh_cn&edition=full","pubTime":"2026-10-15 10:00","pubTimestamp":1792029600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1161","BK4550","IBBQ","159316","159929","BK4588","BK4585","FLHK","MEDX","159892","159992","LNGR","FDN","VXUS","BK1574","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675037153","title":"创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2675037153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675037153?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:59","pubTimestamp":1792029581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走强，截至发稿，百济神州 涨4.11%，翰森制药涨3.14%，中国生物制药涨3.10%，再鼎医药涨2.80%，石药集团涨2.10%，科伦博泰生物涨2.06%。消息面上，里昂发表研究报告指，中国医疗保健板块处周期底部，管线进展有望提振情绪。中国创新资产为世界肺癌大会的重要亮点，料于欧洲肿瘤内科学会大会继续受关注；该行认为，目前各治疗领域的临床领先地位，将塑造未来市场份额。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1993786604.SGD","09688","06978","BK4139","LU2039709279.SGD","BK0239","ONC","BK1589","IE0008369823.USD","IE00BZ08YT58.USD","MEDX","LU0588546209.SGD","IBBQ","BK4585","01177","LU0140636845.USD","LNGR","LU0501845795.SGD","LU0828237510.HKD","LU1951186391.HKD","LU0307460666.USD","IE0008368742.USD","LU1813983027.USD","LU2328871848.SGD","SG9999004220.SGD","HK0000165453.HKD","BK1521","LU1719994722.HKD","BK1583","159992","LU0072913022.USD","LU1008478684.HKD","LU1251922891.USD","LU1303224171.USD","BK4588","LU0314109678.HKD","BK1588","LU0228659784.USD","LU1152091168.USD","LU1770034418.SGD","KURE","03692","LU1226288253.USD","LU1960683339.HKD","06990","688235","LU0067412154.USD","06160","BK1515","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675377294","title":"天风·医药 | 创新药/制药行业及个股2026半年度回顾与展望——天风医药细分领域分析与展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2675377294","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675377294?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:00","pubTimestamp":1792022400,"startTime":"0","endTime":"0","summary":"BD交易落地和新药获批上市销售放量共同驱动行业发展。2026H1制药板块业绩整体承压传统制药板块合计136家上市公司，2026H1板块整体营业收入为2519.04亿元，同比减少1.17%；归母净利润为319.44亿元，同比减少0.48%；扣非归母净利润为274.99亿元，同比减少6.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649154817&idx=2&sn=0a1cd07b7d3d89252231370cfa968fb0&chksm=824cbd8ebc17e106a1b90108ebd30406c413fafca7ee07c39922924bf9bccb39e6bfc4c3b943&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1515","159938","159992","BK1574","BK1161","LNGR","IBBQ","09939","AGNG","06978","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675614543","title":"股市必读：亚太药业新发布《关于签署创新药技术交易合作意向书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675614543","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675614543?lang=zh_cn&edition=full","pubTime":"2026-10-14 02:35","pubTimestamp":1791916510,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，亚太药业报收于5.11元，上涨0.99%，换手率1.54%，成交量11.51万手，成交额5804.73万元。公司公告汇总关于签署创新药技术交易合作意向书的公告2026年10月13日，浙江亚太药业股份有限公司全资子公司盛曜光研与衢州市复大生物医药创新研究院签署《创新药技术交易合作意向书》，拟引进1.1类小分子创新药“一种痤疮治疗用BODIPY类光敏剂”技术包。合作尚需完成尽职调查并签署正式协议，目前仅为意向性约定，不构成法律约束。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK1574","BK0132","002370","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675933070","title":"利润说了算！创新药板块新旧交替，谁会在未来更赚钱？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675933070","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675933070?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:47","pubTimestamp":1791884825,"startTime":"0","endTime":"0","summary":"近期，CS创新药（中证指数，931152.CSI）半山腰上徘徊不定，截至9月12日，近一个月上涨3.18%。其中，昭衍新药（603127.SH）上涨22.63%，艾力斯（688578.SH）下跌22.46%，出现了表现几乎完全对称相反的两只个股，市场资金在如何投票？长尾企业占比九成，头部格局依旧“固化”，创新药板块可能正经历一场深刻的新旧动能转换。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610133894240865.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610133894240865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["MEDX","BK1574","06978","BK1161","LNGR","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675305331","title":"润都股份：公司创新药医保谈判相关信息以官方通知和公司公告为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675305331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675305331?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:48","pubTimestamp":1791877686,"startTime":"0","endTime":"0","summary":"证券之星消息，润都股份(002923)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司创新药是否进了社保？何时公布？润都股份回复：尊敬的投资者，您好！公司创新药盐酸去甲乌药碱注射液医保谈判相关信息，请以官方发布的正式通知和公司公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300022476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK0239","BK1574","BK1161","002923"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157830362","title":"港股创新药概念股集体走低，华昊中天医药-B跌超11%、金斯瑞生物科技跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157830362","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157830362?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:38","pubTimestamp":1791855517,"startTime":"0","endTime":"0","summary":"10月13日，港股创新药概念股集体走低，$华昊中天医药-B(02563)$跌超11%，$金斯瑞生物科技(01548)$跌超10%，$药明合联(02268)$、$晶泰控股(02228)$跌超4%，$药明生物(02269)$、$歌礼制药-B(01672)$跌超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU2039709279.SGD","09939","BK1617","LU0128526141.USD","LU0456827905.SGD","LU0359201612.USD","LU0051755006.USD","LU0819121731.USD","LU0456846285.SGD","LU0823426308.USD","LU0708995583.HKD","SG9999002463.SGD","LU0327786744.USD","HK0000306701.USD","LU0516422366.SGD","BK1515","LU0979878070.USD","LU0244354667.USD","LU2488822045.USD","BK1161","LU0856984785.SGD","HK0000320223.HKD","LU0052750758.USD","LU0828237510.HKD","LU1831875114.USD","IE00B0JY6N72.USD","02268","LU0516423174.USD","LU0708995153.HKD","SG9999002562.SGD","LU0359202008.SGD","LU1188198961.HKD","LU0572944931.SGD","LU1880383366.USD","02563","LU0211977185.USD","LU0228659784.USD","LU1242518931.SGD","LU1720050803.USD","VXUS","LU1242518857.USD","LU0320764243.SGD","LU0516422952.EUR","01548","BK4588","LNGR","KCAI","LU0128522744.USD","LU0516422440.USD","IBBQ","BK1583","LU0140636845.USD","LU1794554557.SGD","LU0043850808.USD","BK4585","LU0561508036.HKD","KURE","02269","LU0029874905.USD","LU2778985437.USD","LU3063872942.SGD","BK1576","LU1688375341.USD","HK0000306685.HKD","LU0326950275.SGD","LU0029874061.USD","LU0634319403.HKD","LU0516423091.SGD","02228","LU0348735423.USD","LU0307460666.USD","BK1610","LU0540923850.HKD","LU0348825331.USD","BK1589","HK0000320264.USD","LU0823426480.USD","01477","LU0463099449.HKD","LU0181495838.USD","LU2476274720.SGD","BK1141","LU0348827113.USD","MEDX","01672","LU0417516738.SGD","06978","LU0417516902.SGD","BK1574","BK1521","LU0320764599.SGD","SG9999014674.SGD","LU2476274308.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674884454","title":"国产创新药“出海”如何走远走实？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674884454","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674884454?lang=zh_cn&edition=full","pubTime":"2026-10-12 06:53","pubTimestamp":1791759180,"startTime":"0","endTime":"0","summary":"一边是对外授权交易持续放量，一边是个别项目在临床、注册环节接连遇阻，冷暖交织的行业现状，正在重塑市场对创新药“出海”的认知。过去很长一段时间，市场习惯于将BD签约视作创新药“出海”成功的标志。但事实上，一纸授权协议只是“出海”征程的起点：它只是将产品送上了全球竞争的赛道，而非终点。由此可见，锻造“出海”全链条能力，仍然是国产创新药“出海”的核心课题。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-10-12/doc-iniuxfmv8587906.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-10-12/doc-iniuxfmv8587906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK1574","159992","IBBQ","LNGR","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899603","title":"清华证研院：创新药板块景气修复与医疗器械自主可控构成9月主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899603","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674899603?lang=zh_cn&edition=full","pubTime":"2026-10-10 15:28","pubTimestamp":1791617326,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯（记者张玮华）清华大学全球证券市场研究院（以下简称“清华证研院”）发布《中国上市公司市值分析月度报告（2026年9月）》。清华证研院院长助理、中国上市公司市值管理研究负责人迟永胜接受上证报记者采访时表示，9月A股市场整体呈现调整回落、估值同步压缩的运行态势；行业方面，房地产、医药生物、银行等板块逆势上涨，价值防御风格占优特征清晰。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202610103891917365.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202610103891917365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["GDOC","159883","BK1574","IEIH","MEDX","LNGR","MDEV","09996","06978","BK1161","BK1583","LGHT","IBBQ","PTH","AGNG","BK1100","159992","HART","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","BK1521","09926","01801","CXO","LU1008478684.HKD","LU0823426308.USD","LU0320764599.SGD","WX","LU0348827113.USD","LU2097828714.EUR","01177","LNGR","MEDX","IE00B5MMRT66.SGD","LU1242518931.SGD","LU1960683339.HKD","06821","LU0572944931.SGD","IE00BZ08YR35.GBP","IBBQ","BK1500","LU2125910500.SGD","02359","159992","LU0307460666.USD","BK1191","IE0008369823.USD","LU2399975544.HKD","01093","LU0348767384.USD","LU1688375341.USD","KCE","02269","00013","LU0561508036.HKD","LU1831875114.USD","LU0067412154.USD","LU2097828557.USD","LU0708995153.HKD","KURE","LU2488822045.USD","LU0149534421.HKD","06160","06978","SG9999002463.SGD","LU0029874905.USD","LU0314109678.HKD","02268","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2674885482","title":"阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885482","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674885482?lang=zh_cn&edition=full","pubTime":"2026-10-09 07:00","pubTimestamp":1791500422,"startTime":"0","endTime":"0","summary":"丨2026年10月9日星期五丨NO.1阿斯利康两款重磅ADC药物在华获批新适应证10月8日，阿斯利康宣布，由阿斯利康和第一三共联合开发和商业化的达卓优（通用名：注射用德达博妥单抗）于9月29日正式获得国家药监局批准，用于治疗不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌成人患者。同日，阿斯利康还宣布，优赫得（通用名：注射用德曲妥珠单抗）也在中国获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093890074039.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093890074039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0060","BK1515","BK0196","IBBQ","159992","LU1781817850.SGD","IPOS","06978","LU1997244956.HKD","LU2097828805.USD","LU0359202008.SGD","LU1997245177.USD","BK0239","LU1064131003.USD","MEDX","BK0183","LU2543165471.USD","600276","01276","09939","LU1255011170.USD","LU2097828474.EUR","LU2097828631.EUR","LNGR","LU2488822045.USD","LU1064130708.USD","LU0405327148.USD","LU1969619763.USD","BK1191","LU2580892789.USD","159938","LU2495084118.USD","LU1328615791.USD","LU1580142542.USD","LU2580892862.HKD","BK1574","LU1146622755.USD","LU0405327494.USD","BK0012","LU2097828557.USD","BK1161","LU2097828714.EUR","LU2289578879.USD","LU1997245094.SGD","LU0359201885.HKD","LU2328871848.SGD","LU0359201612.USD","LU1655091616.SGD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071276","title":"众生药业(002317.SZ)：一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071276","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673071276?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:35","pubTimestamp":1791459349,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 发布公告，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验，于近日获得顶线分析数据。REBUILDING-2临床试验于近日完成数据清理和锁定，获得顶线分析结果，达到主要终点。RAY1225注射液在主要有效性指标以及多种心血管和代谢危险因素改善等多个关键次要有效指标均显著优于安慰剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1161","002317","BK0188","LNGR","IBBQ","MDTX","BK1574","MEDX","06978","PSYK","BK0239","159992","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125293050","title":"永泰生物-B（06978）：王敏慧增持，好仓比例升至8.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125293050","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125293050?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:23","pubTimestamp":1791451380,"startTime":"0","endTime":"0","summary":"王敏慧于2026年2月11日通过场外交易增持永泰生物-B（06978）股份，好仓持股由4376.47万股增至5076.47万股。该笔交易代价性质为放弃对股份或债权证的权利，未经联交所公开市场撮合，不属二级市场直接买卖。王敏慧此次增持前持有永泰生物-B好仓4376.47万股，占比7.09%；增持后持股量为5076.47万股，好仓比例升至8.22%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134285145","title":"永泰生物-B：张军政增持，好仓比例升至8.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134285145","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134285145?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:15","pubTimestamp":1791450904,"startTime":"0","endTime":"0","summary":"张军政于2026年2月11日通过场外交易增持永泰生物-B股份，好仓持股由4376.47万股增至5076.47万股。张军政此次增持前持有永泰生物-B好仓4376.47万股，占比7.09%；增持后持股量为5076.47万股，好仓比例升至8.22%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673896025","title":"港股异动 | 创新药概念股午后跌幅扩大 歌礼制药-B(01672.HK)跌超10% 信达生物(01801.HK)跌近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673896025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673896025?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:01","pubTimestamp":1791439309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","LU0607220059.USD","BK1191","01801","LU2328871848.SGD","LU2488822045.USD","LU1188198961.HKD","06978","KURE","LU0463099449.HKD","LU2097828557.USD","LU2097828631.EUR","HK0000165453.HKD","LU2097828474.EUR","BK1574","BK1583","BK1515","LU0244354667.USD","LU0326950275.SGD","LU1969619763.USD","01672","BK1161","01477","LU2242644610.SGD","LU0149534421.HKD","LU2097828714.EUR","LU0502904849.HKD","LU1831875114.USD","LU0455707207.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0375},{"period":"1month","weight":-0.0128},{"period":"3month","weight":-0.2596},{"period":"6month","weight":-0.8864},{"period":"1year","weight":-0.9094},{"period":"ytd","weight":-0.8686}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":-0.0245},{"period":"3month","weight":-0.0203},{"period":"6month","weight":-0.0802},{"period":"1year","weight":-0.0713},{"period":"ytd","weight":-0.0612}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.024873},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.014208},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.065991},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}